Breaking: @SanofiUS will cut list price of best selling Lantus insulin by 78%.
Yes! This follows similar announcements by @LillyPad and @novonordiskus
#insulin4all
I hoped this will happen and it has. This will help millions in America. @ZacharyBrennan endpts.com/threes-company…
Yes! This follows similar announcements by @LillyPad and @novonordiskus
#insulin4all
I hoped this will happen and it has. This will help millions in America. @ZacharyBrennan endpts.com/threes-company…
List price reduction for Lantus starts Jan 2024.
Lillypad announced that it is launching a Lantus equivalent biosimilar at 78% discount to Lantus starting April 1, 2023. And it’s also interchangeable with Lantus.
Lillypad announced that it is launching a Lantus equivalent biosimilar at 78% discount to Lantus starting April 1, 2023. And it’s also interchangeable with Lantus.
https://twitter.com/vincentrk/status/1630925911624228865
Sanofi has already a Lantus authorized generic at 70% discount to Lantus launched last year. Let the price drops due to competition begin! It’s good for patients.
Read Sanofi press release: @sanofi sanofi.com/en/media-room/…
Read Sanofi press release: @sanofi sanofi.com/en/media-room/…
Sanofi will also cap copay for all insulin products at $35 for commercially insured. A move the other big 2 manufacturers also announced
In total this gets all patients on commercial insurance and uninsured same benefit as what was passed in Inflation Reduction Act for Medicare.
In total this gets all patients on commercial insurance and uninsured same benefit as what was passed in Inflation Reduction Act for Medicare.
When @LillyPad made the surprise announcement on March 1, that it will slash Insulin prices, I hoped the other two manufacturers will follow suit.
They have. In 17 days. Awesome. #insulin4all
They have. In 17 days. Awesome. #insulin4all
https://twitter.com/vincentrk/status/1630927610803806208
Advocacy by so many has worked. I’m thankful.
While I don’t know why these manufacturers are finally acting in this manner after years of increasing prices in lock step, the reasons don’t matter as much to me. It’s good news.
While I don’t know why these manufacturers are finally acting in this manner after years of increasing prices in lock step, the reasons don’t matter as much to me. It’s good news.
We still need policy changes at federal level to make sure these price cuts are enduring.
And to make sure we can lower the prices of other new drugs, especially in my field of cancer where launch prices are sky high.
And to make sure we can lower the prices of other new drugs, especially in my field of cancer where launch prices are sky high.
• • •
Missing some Tweet in this thread? You can try to
force a refresh
